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Abstract
Background: Many diseases striking old adults result in eating difficulties. Indications for selecting individuals
for percutaneous endoscopic gastrostomy (PEG) are unclear and everybody may not benefit from the
procedure.
Objective: The aim of this study was to evaluate indications for and survival after PEG insertion in patients
older than 65 years.
Design and Methods: A retrospective analysis including age, gender, diagnosis, indication, and date of death
was made in 201 consecutive individuals, 94 male, mean age 7997 years, who received a nutritional
gastrostomy.
Results: Dysphagia was present in 86% of the patients and stroke was the most common diagnosis (49%).
Overall median survival was 123 days and 30-day mortality was 22%. Patients with dementia and Mb
Parkinson had the longest survival (i.e. 244 and 233 days), while those with other neurological diseases, and
head and neck malignancy had the shortest (i.e. 75 and 106 days). There was no difference in mortality in
patients older or younger than 80 years, except in patients with dementia.
Conclusions: Old age should not be a contraindication for PEG. A high 30-day mortality indicates that there
is a need of better criteria for selection and timing of PEG insertion in the elderly.
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M
any older patients have nutritional problems
caused by eating difficulties that may be due to
somatic diseases, frailty, or fatigue. When oral
nutrition no longer is possible or sufficient, enteral
nutrition (tube feeding) is an option especially in patients
with a functional gastro-intestinal tract. Percutaneous
endoscopic gastrostomy (PEG) is the preferential route
when the treatment is expected to last for a longer period
of time since it is associated with less treatment failures
and better nutritional status than nasogastric tube
feeding (NGT) (1). Moreover, the risk for complications
is less with PEG than with NGT (1, 2). PEG was
originally described for pediatric use (3), but is today
the most common way of supplying artificial enteral
nutrition also in adults including the elderly. The intent
by using artificial enteral nutrition may be to increase
quality of life or to prolong survival. However, many
studies report 30-day mortality figures after placement of
PEG of around 20% (4 8); that is, figures that would be
unacceptable for any other surgical procedure both from
a patient and a health-economical perspective. There is a
need to find clinical variables that may facilitate the
decision process in order to find the patients that may
benefit most from the procedure. In a review, Mitchell
and Tetroe (9) pointed out some factors that were related
to increased mortality after PEG in patients older than
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hypoalbuminemia. A recent study from Blomberg et al.
showed that low albumin, high CRP, age]65 years, and
body mass index (BMI)B18.5 were associated with
increased 30-day mortality after PEG insertion. Patients
with a combination of low albumin and high CRP levels
had a mortality rate of 20% compared withB3% in
patients with normal values (10).
The aim of this study was to examine the indications
and survival in a consecutive group of elderly individuals
who had received PEG.
Methods
Data for this study was collected between November 2001
and June 2002. Included were all consecutive patients, 65
years or older, that underwent PEG insertion from
January 1997 to December 2000 at the Endoscopy Unit
at Karolinska University Hospital, Huddinge. A retro-
spective survey of four different patient chart systems was
carried out and the last day for the follow-up was in April
2002. Data on diagnosis, indication for PEG, operating
time, removal time, or time of death were collected. The
PEG insertion was performed in the endoscopy suite
using intravenous conscious sedation and local anesthe-
sia. The pull procedure was used to place a 20 Fr silicon
tube with a semirigid inner bumper under endoscopic
control. Antibiotic prophylaxis (Cefuroxim) was adminis-
tered intravenously prior to the procedure. Data of weight
and height were not available. Thirteen patients that
received their PEG for drainage of an obstruction or for
medical supplementation were excluded. For one patient,
the time of insertion of the PEG was not noted. In 10 of
the remaining 201 patients, the date for removal of the
PEG was not retrievable. After these exclusions, the
survival analysis was calculated on 191 patients.
Statistics and ethics
Data are presented as mean (9SD) and median with
range and 95% confidence intervals. For survival analysis
we used the Log-rank test and Kaplan Meier curves
(SPSS and Statistica software programs). The study
followed local ethic considerations conformed to the
Helsinki declaration.
Results
There were 201 patients, 65 years or older, that received a
PEG for nutritional support between 1997 and 2000 at
the Karolinska University Hospital, Huddinge, 107
males, 94 women with a mean age of 79 years (range
65 95). The patients were categorized into seven diag-
nosis groups: stroke, dementia, Mb Parkinson, other
neurological diseases (mainly amyotrophic lateral sclero-
sis [ALS]), malignancies with or without dysphagia, and
miscellaneous. Moreover, they were categorized into three
main groups of indications: dysphagia, inability to eat (as
a consequence of extreme weakness, motor and mobility
problem, and fatigue due to the illness), and nutritional
support (EN was used in combination to oral intake).
Many patients had multiple diseases. Diagnoses of
the patients and the indications for PEG are shown in
Table 1. Stroke was the most common diagnosis (49%)
and malignancies with dysphagia were the second most
common (16%). In 86% of the patients dysphagia was the
indication for PEG.
Median survival was 123 days with a range of 0 1713
days (Fig. 1). Survival in the various diagnosis groups is
shown in Table 2. The 30-day mortality in the total
patient population was 22% and the 90-day mortality was
42%. There were 44 and 33% of the patients that were still
alive after 6 months and after 12 months, respectively.
Patients with Mb Parkinson and dementia had the
longest survival while the patients with other neurological
diseases and malignant esophageal obstructions had the
shortest, with a 1-year mortality of 77% (Table 2).
When patientswere dichotomized according to age over
and under 80 years there was no difference in 1-year
mortality in the whole group, i.e. 70 and 64%, respectively
(ns). Except for patients with dementia, where the corre-
sponding figure for 1-year mortality was 33 and 73%,
respectively (p 0.025) there was no age-related difference
in the various diagnostic subgroups (data not shown).
Twenty patients had their PEG removed after a mean
of 300 days and a median of 200 days. Thirteen of these
20 patients were still alive at the time of the last follow-up
in the year 2002.
Discussion
This retrospective survey over older patients that received
PEG for nutritional treatment found just stroke to be the
most common diagnosis and dysphagia to be responsible
for around 90% of the indications. Median survival was
around 4 months.
Most studies on this subject include adults of all ages
and the mean age is usually around 65 years. We report
data from patients above 65 years. In the literature there
seems to be little agreement on whether to report
indication or diagnosis for a decision to place a PEG.
The prognosis, treatment effect, and survival differed
between the diagnoses. There were different indications
for PEG insertion within each diagnoses and knowing the
indication seems important for planning of medical and
nursing resources needed after the hospital stay. In this
study both indications and diagnoses are reported.
Several of the findings confirm what others have reported
regarding underlying disease, survival, and mortality.
Neurological disease was the dominating cause for PEG
insertion followed by malignancies in the upper GI tract
(5, 11). In the study by Callahan on 150 elderly patients,
41% suffered from stroke, 35% had neuro-degenerative
disorders, and 13% had cancer.
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the present study deviates from previous reports. This
may reflect different treatment strategies. Not only the
decision to start nutritional support by PEG, but also the
timing of this decision in relation to the patients clinical
status is of great importance for the survival outcome. In
our study the median survival time was 123 days, which is
shorter than usually presented. For example, in the study
by Fisman et al. (6) the median survival was 210 days in
175 patients, all above 65 years of age. The 95 patients
with stroke had a median survival of 119 days, which is
less than half of the median survival time of 305 days
reported by James et al. (12) in 126 patients with stroke
and dysphagia and a similar mean age of 80 years. Such
differences may reflect a tendency to decide on PEG
insertion later in the disease process, rather than varia-
tions in the care of the patients after the surgical
procedure. The effect of timing and method of enteral
feeding for dysphagic stroke patients was studied in the
FOOD trial (13). The authors concluded that early tube
feeding might reduce case fatality but at the expense of
increasing the proportion surviving with poor outcome.
Therefore early initiation of PEG feeding was not
supported (13). Since only those patients were enrolled
in whom the responsible clinician was uncertain of the
best feeding practice, the results from this multicentre
trial have to be interpreted with caution.
The results from the FOOD trial and other studies on
EN in stroke patients with dysphagia are reviewed and
analyzed in the ESPEN guidelines on enteral nutrition for
geriatric patients. Treatment with EN is recommended as
soon as possible unless there are compelling reasons
against it in patients with neurological dysphagia. For
long-term nutritional support PEG should be preferred
to NGT, since it is associated with less treatment failures
and better nutritional status (1). Studies on the natural
course of dysphagia after stroke show that spontaneous
remission of the swallowing difficulty occurs 7 14 days T a b l e
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Fig. 1. Survival time, all patients, n 191.
PEG in the elderly
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(page number not for citation purpose)after the acute event in 73% 86% of the patients (4, 14,
15). Intensive swallowing therapy is also recommended to
accompany the treatment (1).
Requests for PEG in order to facilitate care are
prevalent; that is, the staff in geriatric and elderly care
institutions tend to prefer PEG to a temporary naso-
gastric tube or to the time-consuming oral feeding. It has
been reported that one-third of patients received a PEG
due to demands from the community (16). Considera-
tions like this may have implications for the survival
length in populations with PEG.
Dementia is a diagnosis where the benefits of placing a
PEG are questioned. The decision to place a PEG in a
patient with dementia must be taken with ethical
considerations (11, 17 21). ESPEN guidelines do not
recommend enteral nutrition to persons with severe
dementia due to more risks than benefits for persons
with severe dementia and only occasionally in early
and moderate dementia to ensure adequate energy and
nutrient supply and to prevent undernutrition (22).
A Cochrane review by Sampson et al. confirmed this
and concluded that there is insufficient evidence to
suggest that enteral nutrition is beneficial in patients
with advanced dementia (23). The 244 days of median
survival does not support previous observations of a
worsened prognosis for patients with dementia and this
may reflect a tendency for selecting mainly mildly
demented otherwise healthy patients for PEG insertion.
The tripled short-term mortality in patients combining
dementia and age above 80 years indicate that high age
should be a precaution for the decision of PEG even in
patients with milder forms of dementia.
A limitation in this survey is that we have no
information about the patients’ cognitive status at the
time when the PEG insertion took place. Further, our
data do not allow any conclusions about quality of life for
the patients that received PEG. To our knowledge no
studies so far have addressed this question.
In accordance with previous reports, a diagnosis
of malignancy carried a higher risk of short survival (6,
9, 24). However, the difference was less accentuated in
the present study (106 vs. 130 days), when for example
compared to a study by Fisman et al. (6) that reported a
survival of 137 days in patients with malignant disease
versus 321 days in patients with non-malignant disease.
It should be acknowledged that PEG insertion due to
malignant esophageal obstruction could be justified by
palliative reasons even when survival is expected to be
short.
Patients with ALS usually present with a long survival
after PEG insertion (9, 25). In our study the 13 patients
with ‘other neurological diseases’ (12 with ALS) had
the shortest survival time of all. However, the current
patients were notably older (7598 years) compared to
those presented by Mitchell and Tetroe (9) and Chio et al.
(25) (60 and 62 years).
Not unexpectedly, patients older than 80 had a slightly
worse prognosis than those younger than 80, i.e. in line
with other reports (4, 26 28). This age effect was most
pronounced in the patients with dementia. Otherwise the
age effect appeared so small that it would not be
advisable to identify age as a clear unfavorable factor
for PEG in this unselected consecutive group of elderly
patients.
The overall 30-day mortality of 22% is well in
accordance with published data (6, 29), whereas there
are reports on even higher mortality figures of up to 28%
(11, 30). The high short-term mortality in this elderly
population may not be due to procedure-related compli-
cations, but rather to the decisions of PEG placement
taken late in the disease course. The 90-day mortality of
42% and 180 day figure of 56% also corresponds well to
published data of 44 and 52% (11). In the review by
Tetroe and Mitchell (9) the 1-year mortality was 62%,
well in line with our figure of 67% and other reports of 61
Table 2. Median survival in days and 1-,3-, 6-, and 12-month mortality for various diagnostic groups, n 191
Mortality (%)
Median survival in days (95% CI)
Days
30 90 180 365
Dementia (n 16) 244 (49 439) 25 37 37 58
Mb Parkinson (n 11) 233 (0 660) 9 18 36 55
Miscellaneous (n 19) 130 (45 215) 17 39 61 61
Stroke (n 95) 119 (15 223) 22 46 55 67
Malignant obstruction (n 31) 106 (63 149) 23 42 68 77
Other neurological diseases (n 13) 75 (15 135) 23 54 62 77
Other malignancy (n 4) *** **
No data available (n 2) *** **
All patients (n 191) 123 (74 172) 22 42 56 67
Anna Malmgren et al.
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mortality of 50% (5).
We may conclude that there is a major variability in
survival after PEG insertion in elderly patients that suffer
from various diseases. The high 30-day mortality of 22%
in this study is in accordance with published data, but
median survival time appeared to be shorter than
previously reported. Dementia was not found to be a
negative prognostic factor for survival in this population,
especially not in those below the age of 80 years.
However, the limited access to patient data, such as
disease severity and nutritional state, does not allow a
deeper analysis on which clinical variables, which would
be discriminative for selecting patients, would benefit
most from the procedure. According to the recent study
by Blomberg et al., it should not be recommended to
make PEG insertion in patients with CRP levels and low
albumin indicating ongoing inflammation (10).
There is still an urgent need for developing ways to
decide the risk/benefit ratio in the individual patient in
order to optimize the timing and route of nutritional
support. Especially in this field, ethical consideration is a
challenge for the scientific approach, but such efforts
would need prospective randomized controlled studies,
which most likely are not accepted due to ethical
considerations. However, future studies that include
questions regarding quality of life are possible to perform
and are needed to elucidate the ethical aspects of enteral
nutrition treatment in geriatric patients.
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